SCHEMBL5778943

SCHEMBL5778943

Fc1cccc(CNc2cnc3ccccc3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 4/20 0.56
HPGD P15428 4/20 0.56
HTT P42858 3/20 0.56
NPC1 O15118 3/20 0.56
LMNA P02545 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
GFER P55789 1/20 0.56
HDAC6 Q9UBN7 1/20 0.55
APP P05067 2/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
GAA P10253 3/20 0.51
MAPT P10636 3/20 0.51
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
ALOX15 P16050 1/20 0.51
ALOX12 P18054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9093698 0.85 HDAC6 (0.67) KDM4EALDH1A1HPGDHTTNPC1
SCHEMBL28014135 0.78 FLT1 (0.65) KDM4EALDH1A1HPGDHTTNPC1
SCHEMBL5018962 0.77 HDAC6 (0.64) KDM4EALDH1A1HPGDHTTNPC1
SCHEMBL11514391 0.75 FFAR1 (0.63) HPGDLMNASMN1; SMN2HDAC6APP
SCHEMBL28000617 0.75 DYRK1A (0.51) KDM4EALDH1A1HPGDLMNARAB9A
SCHEMBL6692696 0.75 FFAR1 (0.67) ALDH1A1HPGDLMNARAB9AAPP
SCHEMBL28048000 0.74 PDGFRB (0.61) KDM4EALDH1A1HPGDHTTNPC1
SCHEMBL3273212 0.74 LMNA (0.50) LMNASMN1; SMN2APPGAAMAPT
SCHEMBL6696141 0.73 HPGD (0.60) ALDH1A1HPGDLMNAAPPMEN1
SCHEMBL6229701 0.73 HPGD (0.65) ALDH1A1HPGDLMNASMN1; SMN2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562903-A4 MUCIN SYNTHESIS INHIBITORS GENAERA CORP (US) 2006-09-20 EP claimed
EP-1562903-A2 MUCIN SYNTHESIS INHIBITORS Genaera Corporation (US) 2005-08-17 EP claimed
EP-1255544-A4 MUCIN SYNTHESIS INHIBITORS GENAERA CORP (US) 2005-02-02 EP claimed
US-20040254096-A1 Mucin synthesis inhibitors GENAERA CORPORATION 2004-12-16 US claimed
WO-2004043392-A2 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2004-05-27 WO claimed
EP-1418914-A2 MUCIN SYNTHESIS INHIBITORS Genaera Corporation (US) 2004-05-19 EP claimed
US-20030236220-A1 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2003-12-25 US claimed
WO-2003011294-A2 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2003-02-13 WO claimed
EP-1255544-A1 MUCIN SYNTHESIS INHIBITORS MAGAININ PHARMACEUTICALS, INC. (US) 2002-11-13 EP claimed
US-20020165244-A1 Mucin synthesis inhibitors GENAERA CORPORATION 2002-11-07 US claimed
US-20020147216-A1 Mucin synthesis inhibitors GENAERA CORPORATION 2002-10-10 US claimed
US-20010041685-A1 Mucin synthesis inhibitors GENAERA CORPORATION 2001-11-15 US claimed
WO-2001054685-A1 MUCIN SYNTHESIS INHIBITORS GENAERA CORPORATION (US) 2001-08-02 WO claimed
US-7345051-B2 Mucin synthesis inhibitors GENAERA CORPORATION (US) 2008-03-18 US disclosed
EP-1255544-B1 MUCIN SYNTHESIS INHIBITORS GENAERA CORP (US) 2007-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236220-A1 MUCIN SYNTHESIS INHIBITORS MUC1, CFTR, SERPINB1 KDM4E 4561/4885ALDH1A1 1261/4885HPGD 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.